Who Owns Bio-Rad Company?

Who Owns Bio-Rad Laboratories?

Understanding a company's ownership is key to grasping its strategic direction and governance. Bio-Rad Laboratories' journey began with its IPO in 1966, a move that reshaped its shareholder landscape and fueled growth.

The founding family's continued influence, coupled with public investment, creates a unique ownership dynamic. This structure impacts how decisions are made and how the company navigates the competitive life science and diagnostics markets.

Bio-Rad Laboratories, established in 1952, has grown into a significant player in life science research and clinical diagnostics. The company's product portfolio includes a wide range of instruments, software, consumables, reagents, and content for various scientific applications, such as the Bio-Rad BCG Matrix.

As of July 2025, Bio-Rad Laboratories has a market capitalization of approximately $7.2 billion USD. In 2024, the company reported net sales totaling $2.567 billion. The ownership structure is notably influenced by a dual-class share system, which allows the founding family to maintain substantial control while also being a publicly traded entity.

Bio-Rad Laboratories was established in 1952 by David and Alice Schwartz. This husband-and-wife team, both graduates of the University of California, Berkeley, brought their combined expertise in chemistry and biochemistry to the venture. They began their operations from a modest Quonset hut in Berkeley, California, with an initial investment of just $720.

Founding Vision

The founders aimed to accelerate scientific discovery. They focused on providing high-quality tools and products for researchers in the early stages of the company.

Initial Focus

Bio-Rad's early operations centered on innovative ion-exchange materials. They also supplied specialty chemicals vital for biochemical research.

Early Ownership Structure

During its private phase, the Schwartz family held a significant portion of the company's ownership. This reflected their deep commitment and control over the company's direction.

Founding Investment

The company was launched with a modest initial investment of $720. This capital was drawn from the founders' personal savings.

Founders' Expertise

David Schwartz was a chemist, and Alice Schwartz was a biochemist. Their combined scientific backgrounds formed the foundational expertise of Bio-Rad.

Operational Base

The company's initial operations were based out of a Quonset hut. This humble beginning was located in Berkeley, California.

During Bio-Rad's early private phase, the Schwartz family maintained substantial ownership, underscoring their direct control and commitment to the company's foundational direction and product development. While specific details regarding the initial equity split are not publicly available, the founders' vision to accelerate scientific discovery processes by offering high-quality tools and products for researchers was clearly reflected in their strategic decisions. There is no publicly available information detailing early agreements such as vesting schedules, buy-sell clauses, or any initial ownership disputes or buyouts during this period, which is common for companies in their nascent stages and before their Target Market of Bio-Rad was fully established.

Early Ownership Dynamics

The founding family's significant stake in Bio-Rad during its early years was instrumental. It allowed for concentrated decision-making and a clear focus on scientific innovation.

• Founding family maintained substantial ownership.
• Founders' vision guided early strategic decisions.
• No public records of early ownership disputes.
• Initial focus on specialty chemicals and ion-exchange materials.

Complete Bio-Rad Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Bio-Rad Laboratories' journey from a private venture to a publicly traded entity began with its IPO in 1966. The company's stock exchange listings evolved from the American Stock Exchange in 1980 to the New York Stock Exchange in 2008, marking significant milestones in its public ownership history.

The ownership structure of Bio-Rad Laboratories is characterized by a dual-class share system, consisting of Class A and Class B Common Stock. As of February 24, 2025, the company had 22,940,805 shares of Class A and 5,070,337 shares of Class B outstanding. This structure is pivotal, as Class B shares carry significantly more voting power, allowing the founding family to maintain substantial control over strategic decisions despite potentially holding less than 50% of the economic ownership. This arrangement has been instrumental in shaping the company's long-term vision, balancing public market expectations with the enduring influence of its founders.

Bio-Rad's Major Stakeholders and Voting Power

Understanding who owns Bio-Rad Laboratories involves looking at both institutional investors and the founding family's continued influence. The dual-class share system is key to understanding Bio-Rad stock ownership.

• First Eagle Investment Management LLC is a significant institutional investor, holding approximately 10% of the company's shares.
• Vanguard Fiduciary Trust Co. holds about 8.335% of Bio-Rad's stock.
• BlackRock Advisors LLC possesses roughly 7.622% of the outstanding shares.
• The Schwartz family, through its control of Class B shares, retains considerable voting power, influencing the company's strategic direction. Norman Schwartz serves as Chairman and CEO, underscoring this continued family involvement.
• Other notable institutional investors include State Street Global Advisors, Inc. (approximately 2.55%), Blue Raven Partners, L.P., Southeastern Asset Management, Inc., Mawer Investment Management Ltd., Select Equity Group, L.P., and Deerfield Management Company, L.P.
• The history of Bio-Rad Laboratories ownership shows a consistent effort to maintain family influence alongside public market participation.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The board of directors at Bio-Rad Laboratories, a key element in understanding Bio-Rad ownership, reflects a governance structure where the founding family retains significant influence. Norman Schwartz, son of co-founders David and Alice Schwartz, currently holds the positions of Chairman and Chief Executive Officer.

The voting power within Bio-Rad Laboratories is primarily determined by its dual-class share system, a crucial factor for those researching Bio-Rad stock ownership. The company issues Class A (NYSE: BIO) and Class B (NYSE: BIO.B) common stock. Class B shareholders typically have one vote per share, while Class A shareholders have one-tenth of a vote per share on most matters when voting together. However, for director elections, the classes vote separately, with Class A shareholders electing two directors and Class B shareholders electing the remaining five. This structure allows the Schwartz family, as principal holders of Class B shares, to exert considerable control over corporate decisions and board composition, even if their economic stake is not the majority. This system is central to understanding who controls the voting rights at Bio-Rad Laboratories.

Understanding Bio-Rad's Shareholder Structure

Bio-Rad Laboratories operates with a distinct dual-class share system that significantly impacts voting power. This structure is key to identifying Bio-Rad Laboratories majority owner and their holdings.

• Class A and Class B common stock exist.
• Class B shares carry more voting power per share than Class A shares.
• The Schwartz family, as major holders of Class B shares, wield substantial control.
• This system influences director elections and overall corporate governance.
• For a deeper dive into the company's history, explore the Brief History of Bio-Rad.

Bio-Rad Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Recent years have seen significant financial adjustments and strategic moves for Bio-Rad Laboratories, impacting its market valuation and ownership trends. The company has actively engaged in share repurchases, signaling a focus on returning value to shareholders amidst evolving market conditions.

Bio-Rad Laboratories has demonstrated a commitment to shareholder returns through its equity buyback program. In July 2024, the company boosted its buyback authorization by $500 million, bringing the total to $1000 million. During the second quarter of 2025, Bio-Rad repurchased 593,508 shares for $139 million, with $337 million remaining under the current authorization. For the entirety of 2024, share buybacks totaled 691,000 shares, valued at approximately $22 million.

Strategic Acquisition Expands Digital PCR Capabilities

The acquisition of Stilla Technologies, completed in early to mid-2025, is a key development. This move is expected to enhance Bio-Rad’s digital PCR offerings, reinforcing its position in the genomics and applied science markets.

Financial Performance and Outlook

In 2024, Bio-Rad reported net sales of $2,566.5 million, a slight decrease from $2,671.2 million in 2023, mainly due to the Life Science segment. However, the Clinical Diagnostics segment saw a 3.7% sales increase. For 2025, the company revised its revenue growth forecast to 0%-1% on a currency-neutral basis.

Leadership and Ownership Trends

Alice Schwartz, a co-founder, stepped down from the board in 2022. Rajat Mehta took on the role of Executive Vice President of Global Commercial Operations in 2025. Institutional ownership is noted to be increasing, with major investment firms holding significant stakes, reflecting broader market trends and investor confidence in the company's strategic direction and its Mission, Vision & Core Values of Bio-Rad.

Market Position and Future Focus

Bio-Rad's market capitalization has seen a significant decline from August 2020 to August 2025. Despite this, the company continues to prioritize innovation and strategic acquisitions to expand its product portfolio and market reach.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE